Loading...
•
Mar 31, 2025
ResMed Q3 2025 Earnings Report
ResMed reported strong Q3 performance with increased revenue, net income, and earnings per share.
Key Takeaways
ResMed delivered a solid third quarter for FY2025, with revenue reaching $1.29 billion, driven by sustained demand across devices, masks, and SaaS offerings. The company saw improvements in gross margins and profitability, supported by efficient operations and favorable product mix.
Revenue grew to $1.29 billion, an 8% increase year-over-year.
Net income rose to $365 million, reflecting robust demand and margin gains.
Adjusted EPS reached $2.37, driven by strong operational performance.
Cash from operations hit $579 million, supported by tax refunds and high profitability.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
ResMed remains focused on expanding its digital health leadership and addressing global sleep and respiratory health challenges, supported by innovation and patient outreach.
Positive Outlook
- Strong ongoing demand for sleep devices and SaaS solutions.
- Margin expansion supported by product mix and efficiencies.
- Robust operating cash flow, enhanced by tax refunds.
- Continued global expansion with new product launches like NightOwl™.
- Positive clinical support for CPAP efficacy strengthens brand value.
Challenges Ahead
- Unfavorable foreign exchange rates partially offset margin gains.
- Rising employee-related and marketing costs impacted SG&A.
- Macroeconomic uncertainties could affect global healthcare spending.
- Limited commentary on future revenue growth rate.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...